Lung Cancer
Volume 72, Issue 1 , Pages 114-118 , April 2011

Perception of alopecia by patients requiring chemotherapy for non-small-cell lung cancer: A willingness to pay study

  • Mélisande Bernard

      Affiliations

    • Pharmacy, Hôpital Bichat-Claude Bernard, APHP, 46 rue Henri Huchard, 75877 Paris Cedex 18, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 1 40 25 80 99; fax: +33 1 42 63 58 25.
    • ,
  • Mélanie Brignone

      Affiliations

    • Pharmacy, Hôpital Saint Antoine, APHP, Paris, France
    • ,
  • Alain Adehossi

      Affiliations

    • Pharmacy, Centre hospitalier de Beauvais, Beauvais, France
    • ,
  • Samuel Pefoura

      Affiliations

    • Pharmacy, Cliniques Universitaires Saint-Luc, Brussels, Belgium
    • ,
  • Caroline Briquet

      Affiliations

    • Pharmacy, Cliniques Universitaires Saint-Luc, Brussels, Belgium
    • ,
  • Christos Chouaid

      Affiliations

    • Chest Department, Hôpital Saint Antoine, APHP, Paris, France
    • Université Pierre et Marie Curie, Paris, France
    • ,
  • Patrick Tilleul

      Affiliations

    • Pharmacy, Hôpital Saint Antoine, APHP, Paris, France
    • Université René Descartes, Paris, France

Received 29 March 2010 ,Revised 5 July 2010 ,Accepted 11 July 2010.

References 

  1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–592
  2. Boyle P. Favourable trends in cancer mortality in the European Union but no room for complacency. Ann Oncol. 2008;19:605–606
  3. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology. 2008;17:317–328
  4. Carpenter JS, Brockopp DY. Evaluation of self-esteem of women with cancer receiving chemotherapy. Oncol Nurs Forum. 1994;21:751–757
  5. Noh DY, Nam SJ, Ahn SH, Park BW, Lee ES, Lee MK, et al. Association of clinical experiences with patient-reported outcomes among breast cancer surgery patients: breast cancer quality care study. Qual Life Res. 2008;17:215–225
  6. Girgis A, Breen S, Stacey F, Lecathelinais C. Impact of two supportive care interventions on anxiety, depression, quality of life, and unmet needs in patients with nonlocalized breast and colorectal cancers. J Clin Oncol. 2009;27:6180–6190
  7. Helbekkmo N, Strøm HH, Sundstrøm SH, Aasebø U, Von Plessen C, Bremnes RM Norwegian Lung Cancer Study Group. Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol. 2009;48:1019–1025
  8. Manser RL, Wright G, Byrnes G, Hart D, Conron M, Carter R, et al. Validity of the assessment of quality of life (AQoL) utility instrument in patients with operable and inoperable lung cancer. Lung Cancer. 2006;53:217–229
  9. Munstedt K, Manthey N, Sachsse S, Vahrson H. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer. 1997;5:139–143
  10. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer. 2002;95:155–163
  11. McGarvey EL, Baum LD, Pinkerton RC, Rogers LM. Psychological sequelae and alopecia among women with cancer. Cancer Pract. 2001;9:283–289
  12. Hesketh PJ, Batchelor D, Golant M, Lyman GH, Rhodes N, Yardley D. Chemotherapy-induced alopecia: psychological impact and therapeutic approaches. Support Care Cancer. 2004;12:543–549
  13. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  14. Potière C, Moatti JP, Maraninchi D, Viens P. Choice and elicitation of preferences, toward therapeutic decision sharing in cancerology: from economic theory to medical practice. Bull Cancer. 1998;85:173–179
  15. Aristides M, Chen J, Schulz M, Williamson E, Clarke S, Grant K. Conjoint analysis of a new chemotherapy: willingness to pay and preference for features of raltitrexed versus standard therapy in advances colorectal cancer. Pharmacoeconomics. 2002;20:775–784
  16. Gafni A. Willingness to pay: what's in name. Pharmacoeconomics. 1998;14:465–470
  17. Olsen JA, Smith RD. Theory versus practice: a review of “Willingness To Pay” in health and health care. Health Econ. 2001;10:39–52
  18. Franic DM, Pathak DS, Gafni A. Quality-adjusted life years was a poor predictor of women's willingness to pay in acute and chronic conditions: results of survey. J Clin Epidemiol. 2005;58:291–303
  19. Morris J, Lecturer S. Willingness to pay for new chemotherapy for advanced ovarian cancer. N Z Med J. 2000;113:143–146
  20. Dranitsaris G, Elia-Pacitti J, Cottrell W. Measuring treatment preferences and willingness to pay for docetaxel in advanced ovarian cancer. Pharmacoeconomics. 2004;22:375–387
  21. Tan Sean P, Chouaid C, Hettler D, Baud M, Hejblum G, Tilleul P. Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy. Curr Med Res Opin. 2009;25:1455–1460
  22. Brown A, Aristides M, FitzGerald P, Liepa A, Boyer M, Clarke S. Patient preference and willingness to pay for permetrexed versus docetaxel in the second line treatment of advanced non small cell lung cancer: a discrete choice conjoint analysis. In: ISPOR outcomes research digest, PCN7, 2nd Asia-Pacific conference. Shanghai, China 5–7 March. 2006;
  23. Leighl NB, Tsao WS, Zawisza DL, Nematollahi M, Shepherd FA. A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer. Lung Cancer. 2006;51:115–121
  24. Slevin ML, Stubbs L, Plant HJ, Wilson P, Gregory WM, Armes PJ, et al. Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public. BMJ. 1990;300:1458–1460
  25. Yasunaga H, Ide H, Imamura T, Ohe K. The measurement of willingness to pay for mass cancer screening with whole-body PET (positron emission tomography). Ann Nucl Med. 2006;20:457–462
  26. Dranitsaris G, Leung P, Ciotti R, Ortega A, Spinthouri M, Liaropoulos L, et al. A multinational study to measure the value that patients with cancer place on improved emesis control following cisplatin chemotherapy. Pharmacoeconomics. 2001;19:955–967

PII: S0169-5002(10)00364-8

doi: 10.1016/j.lungcan.2010.07.004

Lung Cancer
Volume 72, Issue 1 , Pages 114-118 , April 2011

Article Tools

* Image Usage & Resolution